Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
Delayed Quote. Delayed London Stock Exchange - 09/24 11:35:14 am
8845 GBX   +2.04%
01:15pHealth Care Stocks Retreat Friday
MT
12:19pEurostoxx 50 : European stocks slip on Evergrande woes, weak German business morale
RE
11:21aEuropean ADRs Move Lower in Friday Trading
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Astrazeneca : H1 2021 results

07/30/2021 | 11:43am EDT

Astrazeneca - H1 2021 results

Pascal Soriot, Chief Executive Officer, commenting on the results said: 'AstraZeneca has delivered another period of strong growth thanks to robust performances across all regions and disease areas, particularly Oncology, New CVRM and Fasenra in Respiratory.

As a result, we have delivered further earnings progression, supported ongoing launches, and continued our investment in R&D.

We continue to advance our portfolio of life-changing medicines with further significant progress across disease areas. In Oncology, we recently presented Lynparza's OlympiA Phase III trial at the plenary session of the 2021 American Society of Clinical Oncology Annual Meeting, and we also shared the final results from Calquence's head-to-head trial with ibrutinib. In BioPharmaceuticals, the US approved Farxiga for chronic kidney disease and granted tezepelumab Priority Review to treat patients with asthma. Alexion will enable us to enhance our pipeline, extending the Company's presence in rare diseases and immunology with its complement biology.

Following the successful acquisition of Alexion, we are today updating our full-year 2021 guidance; our long-term goals to accelerate scientific discovery, invest for sustainable growth and deliver more benefits for patients remains unchanged.'

Contact:

Tel: +44 (0)20 3749 5000

(C) 2021 Electronic News Publishing, source ENP Newswire

All news about ASTRAZENECA PLC
01:15pHealth Care Stocks Retreat Friday
MT
12:19pEurostoxx 50 : European stocks slip on Evergrande woes, weak German business morale
RE
11:21aEuropean ADRs Move Lower in Friday Trading
MT
10:06aASTRAZENECA : Receives a Buy rating from Barclays
MD
09:21aWall Street Tumbles Pre-Bell, Evergrande Risks Resurface
MT
09:15aHealth Care Stocks Slip Pre-Bell Friday
MT
08:59aIMPERIAL COLLEGE LONDON : Imperial RNA technology to be developed by VaxEquity with AstraZ..
AQ
08:26aDEPARTMENT OF HEALTH AND SOCIAL CARE : check the rules for travel to England from abroad
AQ
07:35aASTRAZENECA : Lynparza in combination with abiraterone significantly delayed disease progr..
AQ
06:46aASTRAZENECA : LYNPARZA« (olaparib) in combination with abiraterone significantly delayed d..
BU
More news
Analyst Recommendations on ASTRAZENECA PLC
More recommendations
Financials (USD)
Sales 2021 35 401 M - -
Net income 2021 5 006 M - -
Net Debt 2021 24 250 M - -
P/E ratio 2021 33,8x
Yield 2021 2,33%
Capitalization 187 B 187 B -
EV / Sales 2021 5,98x
EV / Sales 2022 4,85x
Nbr of Employees 76 100
Free-Float 96,3%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 27
Last Close Price 120,91 $
Average target price 136,24 $
Spread / Average Target 12,7%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Aradhana Sarin Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas NICOLAS Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC20.77%184 418
JOHNSON & JOHNSON4.44%433 991
ROCHE HOLDING AG10.87%324 441
PFIZER, INC.20.05%247 760
NOVO NORDISK A/S51.58%233 750
ELI LILLY AND COMPANY37.22%210 490